Kraig Biocraft Laboratories Targets New Industrial and Defense Biomaterials as "Project Atlas" Hits Major Milestone
MWN-AI** Summary
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) has announced a significant milestone in "Project Atlas," a cutting-edge bioengineering initiative focused on developing new biomaterials for industrial and defense applications. First introduced in January 2026, Project Atlas aims to merge various genetic elements into an integrated system, creating super materials with enhanced strength and toughness. Kim Thompson, the Founder and CEO of Kraig Labs, hailed this project as a groundbreaking advancement in molecular biology related to material science, noting the unprecedented coordination of genetic engineering involved.
As Project Atlas progresses, it has already resulted in multiple new transgenic lines, which are currently being evaluated. The early outcomes have bolstered Kraig Labs' confidence that the project will revolutionize biomaterial development and broaden the applications of spider silk and other advanced fibers. This progress comes as Kraig Labs is gaining international acclaim for its pioneering efforts in bioengineering, recently featured on the cover of the March 2026 issue of National Geographic, emphasizing the significance of its innovations in spider silk production.
Kraig Labs is optimistic about the continued swift advancement of Project Atlas, aiming to create new materials tailored to meet rigorous industrial and defense standards. The company is recognized as a leader in spider silk technology, which has profound implications for the global textile industry, while also establishing a new horizon for material capabilities. As Project Atlas enters its next phase, stakeholders and interested parties are encouraged to stay updated via the company’s website and digital channels.
For further information, Kraig Labs invites inquiries from investors and interested individuals.
MWN-AI** Analysis
Kraig Biocraft Laboratories, Inc. (KBLB) has recently announced a significant advancement in its "Project Atlas", a pioneering initiative aimed at developing advanced biomaterials for industrial and defense applications. This project underscores Kraig's commitment to leveraging spider silk technology—a field that has been gaining substantial recognition, as evidenced by recent features in esteemed publications like National Geographic.
The successful completion of a critical milestone in Project Atlas positions Kraig Labs as a potential leader in the biomaterials sector. The project's goal to integrate various genetic modifications to create new super materials signifies a transformative approach in material science, with potential applications ranging from textiles to high-performance defense gear.
Investors should approach KBLB with cautious optimism. The positive trajectory of Project Atlas could significantly impact the company’s growth, potentially leading to increased revenue streams as new materials hit the market. The emphasis on industrial and military applications aligns with growing demands for innovative solutions in these sectors, suggesting that Kraig’s products may meet essential performance standards that current materials struggle to fulfill.
However, it is essential to acknowledge the inherent risks associated with biotech investments, particularly those involved in research and development. While management expresses confidence in the anticipated outcomes from Project Atlas, the ambitious nature of this initiative carries uncertainties that could affect share price volatility.
Potential investors should stay informed on upcoming phases of Project Atlas and monitor the company's ability to translate laboratory successes into commercially viable products. Given the recent accolades and growing recognition, KBLB presents an intriguing opportunity but should be approached with a diversified investment strategy to mitigate risks associated with emerging technologies.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
ANN ARBOR, Mich., March 05, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced a major milestone in "Project Atlas", the Company's next-generation bioengineering initiative aimed at creating entirely new classes of materials for industrial and defense applications.
Kraig Labs first disclosed the existence of Project Atlas on January 19th, 2026, when it was already at an advanced stage of development. The Company described an ambitious effort to merge numerous complex genetic elements into a single integrated architecture. Project Atlas seeks to create new super materials with enhanced strength, toughness, and other properties. Today, Kraig Labs confirms Project Atlas has passed its most critical milestone and is moving forward at full speed.
Project Atlas employs numerous genetic modifications operating in tandem to create an entirely new class of materials. The result is a powerful new approach to biomaterial development, opening the door to entirely new performance capabilities.
"This project represents what I believe is the most advanced molecular biology work ever undertaken in material science," said Kim Thompson, Founder and CEO of Kraig Labs. "We are creating an advanced platform, where multiple components work in unison to achieve very specific material outcomes. That level of coordinated engineering has never been attempted before in spider silk or biomaterials, to our knowledge."
Atlas has already resulted in the creation of multiple new transgenic lines, which are now progressing through the Company's evaluation pipeline.
Early results have reinforced management's confidence that Project Atlas will reshape the future of biomaterial development and significantly broaden the applications for spider silk and other super fibers.
This latest breakthrough comes as Kraig Labs continues to receive global recognition for its pioneering work in bioengineered spider silk. The Company was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of its work in bioengineering and scaling spider silk production.
| ** |
With Project Atlas now moving into its next phase, Kraig Labs expects continued rapid progress as the program advances toward the creation of new materials designed to meet demanding industrial and defense performance requirements.
Interested persons can order a copy of National Geographic featuring Kraig Labs at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.
You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering.
** Photography by Mark Thiessen, NGM Staff, Image Copyright: National Geographic Magazine
For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.
For details about recent Kraig Labs advancements, please watch the Company's investor updates at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.
* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/.
Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward-looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, Inc.
(720) 288-8495
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c9c3f5f6-4ce3-4914-9923-47200573a16e
FAQ**
How does Kraig Biocraft Labs Inc KBLB plan to leverage the advancements from Project Atlas to secure partnerships in the industrial and defense sectors?
What specific applications for the new materials developed from Project Atlas does Kraig Biocraft Labs Inc KBLB foresee having the greatest market potential?
How will the success of Project Atlas impact Kraig Biocraft Labs Inc KBLB's financial forecasts and investor confidence in the coming years?
What strategies is Kraig Biocraft Labs Inc KBLB implementing to mitigate the risks associated with the ambitious goals of Project Atlas?
**MWN-AI FAQ is based on asking OpenAI questions about Kraig Biocraft Labs Inc (OTC: KBLB).
NASDAQ: KBLB
KBLB Trading
-1.42% G/L:
$0.1252 Last:
539,152 Volume:
$0.1255 Open:
